Teduglutide for pediatric short bowel syndrome patients

Expert Rev Gastroenterol Hepatol. 2021 Apr 2. doi: 10.1080/17474124.2021.1913052.Online ahead of print.

Beatrice E Rosete 1 2, Danielle Wendel 2 3, Simon P Horslen 2 4


Author information

  • 1Department of Pharmacy, Seattle Children's Hospital, Seattle, WA, USA.
  • 2School of Pharmacy, University of Washington, Seattle, WA, USA.
  • 3Department of Gastroenterology, Hepatology and Nutrition, Seattle Children's Hospital, Seattle, WA, USA.
  • 4Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA.


Introduction: The goal for pediatric short bowel syndrome (SBS) patients is intestinal adaptation. Until recently, the medical management of pediatric SBS has centered on the prevention and treatment of complications in order to allow time for adaptation. Teduglutide, glucagon-like peptide 2 (GLP-2) analogue has recently been approved for use in pediatric SBS patients greater than 1 year of age as a novel agent to augment intestinal adaptation. This article reviews and educates the reader on this novel pharmacologic therapy and its use in pediatrics.Areas covered: This article reviews the pharmacology, safety, efficacy, and tolerability of GLP-2 analogue teduglutide in pediatric patients greater than 1 year of age. We review all current studies and discuss teduglutide's place in pediatric SBS therapy.Expert opinion: Teduglutide marks the first successful pharmacological intervention that augments the natural process of adaptation safely and effectively in SBS pediatric patients. More studies and further development are needed to optimize its potential in other pediatric patients.

© Copyright 2013-2021 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.